6533b829fe1ef96bd1289b07
RESEARCH PRODUCT
Correlation between clinical response and urinary interleukin levels using different doses and intravesical administration schedules of interferon-alpha-2b combined with epirubicin: a pilot study
Sergio SalernoFrancesco GervasiMichele Pavone-macalusoDomenico LioG. CorselliVincenzo SerrettaB. Piazzasubject
Nephrologymedicine.medical_specialtyUrologyUrinary systemUrologyAlpha interferonIntravesical immunotherapyUrineInterferon alpha-2PharmacologyDrug Administration ScheduleIntravesical chemotherapyInterferon-alpha-2bSettore MED/24 - UrologiaInternal medicinemedicineHumansCombined Modality TherapyEpirubicinbusiness.industryInterleukinsInterferon-alphaInterleukinCombined Modality TherapyRecombinant ProteinsClinical trialInterleukins (urinary concentration of)Administration IntravesicalUrinary Bladder NeoplasmsInterleukin-2Interleukin-4Neoplasm Recurrence LocalbusinessInterleukin-1Epirubicinmedicine.drugdescription
A total of 62 patients at high risk for recurrence of superficial bladder cancer were selected for a study designed to compare the prophylactic efficacy of different doses and schedules of sequential intravesical instillations of epirubicin and interferon-alpha-2b and to evaluate which sequence could enhance the release of cytokines in the urine. Our investigations showed a significant increase in urinary concentrations of interleukins in patients who received the sequential intravesical administration of epirubicin and interferon-alpha-2b. Higher urinary concentrations of interleukins and a lower recurrence rate were detected in patients who received interferon-alpha-2b 24 h after epirubicin instillation. © 1993 Springer-Verlag.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 1993-09-01 | Urological Research |